Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENOVATE
2023-509838-19-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Musculoskeletal aging, osteoporosis and Sarcopenia comparing Everolimus (Afinitor) with Placebo (2 arms). Primary endpoint: Change in serum bone formation marker P1NP. Planned start Mar 2024; status: authorised.
02
Drugs
everolimus
03
Conditions
Musculoskeletal agingosteoporosisSarcopenia
Beyond the preview
Go deeper on 2023-509838-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509838-19-00.